medigraphic.com
ISSN 2070-8718 (Print)

2020, Number 1

<< Back Next >>

Rev Cub Gen 2020; 13 (1)

Aallelic variants *3, *4, *5 and *6 of gene CYP2D6 in a sample of Cuban patients with schizophrenia

Roblejo BH, Marcheco TB, Monzón BG, Marín PLC, Esperón ÁAA, Collazo MT, Llerena RA

Language: Spanish
References: 18
Page: 1-11
PDF size: 458.87 Kb.


ABSTRACT

Introduction: The CYP2D6 gene encodes the namesake protein, the main enzyme in the complex of cytochromes P-450 in phase I of the metabolism of many drugs widely used in clinical practice, among them the neuroleptics. The allelic variants implying a null function of this enzyme: *3, *4, *5 and *6, predict 93%-97.5% of the possible slow metabolizer phenotypes, which cause an accumulation of toxic concentrations and therefore a higher risk of adverse reactions. On the other hand, a number of studies report a low frequency of slow metabolizers in patients with schizophrenia.
Objective: Evaluate the association between the non-functional variants of the CYP2D6 gene and schizophrenia in Cuban patients.
Methods: A case-control study was conducted. The case group was composed of 212 patients with schizophrenia, whereas the controls were 326 healthy volunteers.
Results: The frequencies of CYP2D6 alleles with null enzymatic activity were similar in the two groups. A statistically significant difference of slow metabolizers was not found among patients with schizophrenia or healthy volunteers.
Conclusions: In the study conducted, the slow predictive metabolizer phenotype of the CYP2D6 gene was not a predisposing factor for schizophrenia.


REFERENCES

  1. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T. Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine. 2017;19(1):69-76.

  2. Peñas-Lledo EM LA. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. British journal of clinical pharmacology. 2014;77(4):673-83.

  3. Chen J CF, Liu L, Wang L, Chen X. Genetic studies of schizophrenia: an update. Neurosci Bull. 2015;31(1):87-98.

  4. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P-450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017;102(4):688-700.

  5. Llerena A, Ramírez R, González I, Álvarez M, Peñas-Lledó E, et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. The pharmacogenomics journal. 2010;12(2):176-83.

  6. Dahl AA, Løwert A, Asserson S, Bjarking L, Berglund J, Kristensen F, et al. Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark. Human Psychopharmacology: Clinical and Experimental. 1998;13(7):509-11.

  7. Brockmoller J KJ, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, et al. The impact of the CYP2D6 polymorphim on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72(4):438-52.

  8. Llerena A, Dorado P, Penas-Lledo EM, Caceres MC, De la Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. The pharmacogenomics journal. 2007;7(6):408-10.

  9. Niwa T, Shizuku M, Yamano K. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P-450 2D6. Archives of Biochemistry and Biophysics. 2017;620:23-7.

  10. Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenetics and genomics. 2007;17(5):339-47.

  11. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Gesteira A, Barros F, et al. Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. Pharmacogenomics. 2009;10(9):1457-66.

  12. Roblejo Balbuena H. Polimorfismos del gen CYP2D6 y su relación con la esquizofrenia. Revista del Hospital Psiquiátrico de La Habana. 2016;13(1).

  13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids research. 1988;16(3):1215-9.

  14. Nomenclature CDa. CYP2D6 allele nomenclature. Cytochrome P-450 Allele Nomencl. Database. Hum Genet. 2015 [acceso: 17/01/2019]. Disponible en: https://www.pharmvar.org ›index_original

  15. Llerena Aea. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opinion on Drug Metabolism & Toxicology. 2014;10(11):1569-83.

  16. Don CG, Smiesko M. Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function. 2018;13(8):e0202534. DOI: https://doi.org/10.1371/journal.pone.0202534

  17. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics and genomics. 2007;17(2):93-101.

  18. Álvarez S, Mas S, Gasso P, Bernardo M, Parellada E, Lafuente A. Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. Fundamental & clinical pharmacology. 2010;24(6):741-7.




2020     |     www.medigraphic.com